Press Releases

11/30/22
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
Printer Friendly Version 
11/10/22
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
Printer Friendly Version 
11/03/22
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Printer Friendly Version 
11/01/22
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
Printer Friendly Version 
11/01/22
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Printer Friendly Version 
11/01/22
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Printer Friendly Version 
10/26/22
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Printer Friendly Version 
10/18/22
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
Printer Friendly Version 
10/04/22
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
Printer Friendly Version 
09/10/22
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
Printer Friendly Version 
09/07/22
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
Printer Friendly Version 
09/06/22
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
Printer Friendly Version 
08/09/22
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Printer Friendly Version 
07/26/22
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Printer Friendly Version 
07/11/22
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Printer Friendly Version 
07/07/22
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Printer Friendly Version 
07/05/22
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
Printer Friendly Version 
06/21/22
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Printer Friendly Version 
06/16/22
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
Printer Friendly Version 
05/31/22
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
Printer Friendly Version 
05/26/22
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Printer Friendly Version 
05/26/22
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
Printer Friendly Version 
05/10/22
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
Printer Friendly Version 
05/04/22
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
Printer Friendly Version 
05/03/22
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Printer Friendly Version 
04/26/22
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Printer Friendly Version 
04/14/22
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Printer Friendly Version 
04/13/22
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Printer Friendly Version 
03/25/22
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Printer Friendly Version 
03/14/22
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Printer Friendly Version 
03/02/22
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March
Printer Friendly Version 
02/17/22
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Printer Friendly Version 
02/14/22
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Printer Friendly Version 
02/03/22
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
Printer Friendly Version 
02/02/22
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
Printer Friendly Version 
01/18/22
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
Printer Friendly Version 
01/09/22
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
Printer Friendly Version 
01/06/22
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Printer Friendly Version 
01/05/22
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
Printer Friendly Version 
01/04/22
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
Printer Friendly Version 
01/04/22
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Printer Friendly Version 

Receive Email Alerts

Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Sign Up.